Transforming precision science into life-changing oncology therapies
Tethra Biosciences is a clinical-stage biotechnology company advancing differentiated therapies for patients with difficult-to-treat cancers across solid tumors and hematologic malignancies.
About Tethra
Founded on the belief that meaningful innovation lies at the intersection of scientific rigor and patient need, we unite world‑class expertise in oncology, translational science, and drug development to advance differentiated therapies from discovery through the clinic.
- Clinical stage: Programs advancing in oncology and hematology.
- Patient‑centric: Every decision anchored in patient impact.
- Disciplined development: Science‑led and data‑driven execution.
Our mission
Build a world‑class oncology company defined by science, speed, and purpose. We identify and develop therapies that target key drivers of the cancer process.
- Advance transformative programs that address high‑unmet needs in oncology and hematology.
- Operate with focus and agility so every decision accelerates patient impact.
- Build long‑term value through strong science, disciplined development, and strategic collaboration.
Our science
We focus on selective kinase inhibition, targeting key regulators of the cell cycle, epigenetic remodeling, and DNA damage repair. By precisely modulating these pathways, we aim to disrupt tumor growth and overcome resistance.
- Cell‑cycle regulation
- Epigenetic remodeling
- DNA damage repair
Plogosertib
A potent and selective PLK1 inhibitor in clinical development for solid tumors and hematologic malignancies. PLK1 plays a central role in cell division and is overexpressed in many cancers. Plogosertib’s differentiated selectivity and pharmacologic profile position it as a potentially best‑in‑class therapy for tumors sensitive to PLK1 inhibition.
- Advancing through early clinical development.
- Clear focus on defining patient benefit and safety.
- Executing a streamlined path to registration.